lundi 29 septembre 2014

Nivolumab shows signs of superior response rate compared to standard chemotherapy in advanced melanoma

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data.

Nivolumab shows signs of superior response rate compared to standard chemotherapy in advanced melanoma

Aucun commentaire:

Enregistrer un commentaire